PT2524060T - Ensaio para a deteção de anticorpos contra o vírus jc - Google Patents

Ensaio para a deteção de anticorpos contra o vírus jc

Info

Publication number
PT2524060T
PT2524060T PT117323154T PT11732315T PT2524060T PT 2524060 T PT2524060 T PT 2524060T PT 117323154 T PT117323154 T PT 117323154T PT 11732315 T PT11732315 T PT 11732315T PT 2524060 T PT2524060 T PT 2524060T
Authority
PT
Portugal
Prior art keywords
assay
virus antibodies
antibodies
virus
Prior art date
Application number
PT117323154T
Other languages
English (en)
Portuguese (pt)
Inventor
Subramanyam Meena
Gorelik Leonid
J Simon Kenneth
Marie Rushe Mia
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44305841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2524060(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of PT2524060T publication Critical patent/PT2524060T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT117323154T 2010-01-11 2011-01-11 Ensaio para a deteção de anticorpos contra o vírus jc PT2524060T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29404810P 2010-01-11 2010-01-11
US31619310P 2010-03-22 2010-03-22

Publications (1)

Publication Number Publication Date
PT2524060T true PT2524060T (pt) 2018-03-28

Family

ID=44305841

Family Applications (3)

Application Number Title Priority Date Filing Date
PT221912595T PT4152004T (pt) 2010-01-11 2011-01-11 Ensaio para a deteção de anticorpos contra o vírus jc
PT172031783T PT3339865T (pt) 2010-01-11 2011-01-11 Ensaio para a deteção de anticorpos contra o vírus jc
PT117323154T PT2524060T (pt) 2010-01-11 2011-01-11 Ensaio para a deteção de anticorpos contra o vírus jc

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT221912595T PT4152004T (pt) 2010-01-11 2011-01-11 Ensaio para a deteção de anticorpos contra o vírus jc
PT172031783T PT3339865T (pt) 2010-01-11 2011-01-11 Ensaio para a deteção de anticorpos contra o vírus jc

Country Status (27)

Country Link
US (2) US9316641B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (4) EP3339865B9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5946218B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101877576B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN102906278A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2011203815B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112012017014B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2784137A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1119972T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (3) DK4152004T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2930469T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (2) FI4152004T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (3) HRP20221390T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (3) HUE060312T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2012DN06139A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (3) LT3339865T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME03026B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX341991B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2524060T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ600681A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (3) PL4152004T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (3) PT4152004T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (3) RS56977B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (2) SG181653A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (3) SI4152004T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (3) SMT202200445T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2011085369A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3264094T3 (da) 2005-04-04 2020-11-23 Biogen Ma Inc Fremgangsmåder til evaluering af en immunrespons på et terapeutisk middel
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
ES2663377T3 (es) 2006-03-03 2018-04-12 Biogen Ma Inc. Métodos para el tratamiento de enfermedades inflamatorias y autoinmunes con natalizumab
ES2989929T3 (es) 2009-10-11 2024-11-28 Biogen Ma Inc Ensayos relacionados con anti-VLA-4
CN102906278A (zh) 2010-01-11 2013-01-30 比奥根艾迪克Ma公司 用于jc病毒抗体的测定
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
EP4187248A1 (en) * 2011-05-31 2023-05-31 Biogen MA Inc. Method of assessing risk of pml
WO2013087601A2 (en) * 2011-12-12 2013-06-20 Janssen Diagnostics Bvba Polyomavirus peptide sequences
WO2013158674A1 (en) * 2012-04-16 2013-10-24 Board Of Regents, The University Of Texas System Detection of extracellular jcv micrornas
WO2013192100A1 (en) 2012-06-18 2013-12-27 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for detecting jc virus
JP6407165B2 (ja) * 2012-12-31 2018-10-17 ニューリミューン ホールディング エイジー ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体
US9949671B2 (en) 2013-03-13 2018-04-24 Orthoaccel Technologies, Inc. Diagnostic mouthpieces
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml
US10955422B2 (en) 2014-02-27 2021-03-23 Biogen Ma, Inc. Method of assessing risk of PML
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
IT201600083859A1 (it) * 2016-08-09 2018-02-09 Univ Degli Studi Di Ferrara Immunosaggio per l’identificazione di anticorpi contro il virus Polioma JC (JCPyV) mediante l’uso di peptidi sintetici.
US20210002372A1 (en) * 2018-03-02 2021-01-07 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating natalizumab-associated progressive multifocal encephalopathy

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
ES2184734T3 (es) 1987-04-27 2003-04-16 Inverness Medical Switzerland Dispositivo de prueba analitica para realizar ensayos de union especifica.
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4818677A (en) 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5118630A (en) 1988-11-04 1992-06-02 Quidel Corporation Method for determining periodic infertility in females
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5084828A (en) 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US5223220A (en) 1990-03-27 1993-06-29 Pacific Biotech, Inc. Solid phase immunoassay device and method of making same
US5118428A (en) 1990-11-13 1992-06-02 Quidel Method to remove red blood cells from whole blood samples
DE4139840B4 (de) 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
JP2868900B2 (ja) 1991-01-11 1999-03-10 クイデル コーポレイション ワンステップ側方流非吸収性アッセイ
US5213796A (en) 1991-05-06 1993-05-25 Dana Farber Cancer Institute Assay for polyomavirus in humans and uses thereof
US5225328A (en) 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US5686315A (en) 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
WO1993015217A1 (en) 1992-02-04 1993-08-05 Quidel Corporation Simplified extraction method for bacterial antigens using dried reagents
US5541069A (en) 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
JP2948318B2 (ja) 1992-03-10 1999-09-13 クイデル コーポレイション 特異的結合アッセイ用の赤血球の分離方法
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5434057A (en) 1994-02-02 1995-07-18 Quidel Corporation Sperm motility assay and devices
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
US5786220A (en) 1995-04-28 1998-07-28 Quidel Corporation Assays and devices for distinguishing between normal and abnormal pregnancy
US6319676B1 (en) 1995-05-02 2001-11-20 Carter Wallace, Inc. Diagnostic detection device and method
US5773234A (en) 1995-08-07 1998-06-30 Quidel Corporation Method and device for chlamydia detection
DE19543553B4 (de) 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6305377B1 (en) 1996-12-12 2001-10-23 Michael T. Portwood System and method for improving compliance of a medical regimen
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US7171371B2 (en) 1999-09-03 2007-01-30 Smg Trust Method and system for providing pre and post operative support and care
JP2003511698A (ja) 1999-10-12 2003-03-25 コンネクス・ゲゼルシャフト・ツーア・オプティミエルング・フォン・フォルシュング・ウント・エントヴィックルング・エムベーハー 便中の酸耐性微生物の改良された検出方法
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
AU783110B2 (en) 1999-12-16 2005-09-22 Biogen Ma Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
WO2001075449A1 (fr) 2000-03-30 2001-10-11 Nippon Kayaku Kabushiki Kaisha Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif
US6620626B1 (en) 2000-08-09 2003-09-16 Mission Research Corp. Antigen detection device and method
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
CA2463678A1 (en) 2000-10-17 2002-04-25 Besst-Test Aps Assay for directly detecting a rs virus related biological cell in a body fluid sample
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6485460B2 (en) 2001-01-12 2002-11-26 Bracco Diagnostics, Inc. Tamper evident syringe barrel
CA2457930C (en) 2001-08-20 2012-06-19 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
WO2003016902A1 (en) 2001-08-20 2003-02-27 Proteome Systems Intellectual Property Pty Ltd Diagnostic testing process and apparatus
US6605602B1 (en) 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
TW201125584A (en) 2002-02-25 2011-08-01 Elan Pharm Inc Pharmaceutical composition for determining efficacy of chronic treatment of inflammation
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
AU2003243642A1 (en) 2002-06-21 2004-01-06 Mckesson Automation Inc. Closed loop medication use system and method
US20070275481A1 (en) 2003-11-24 2007-11-29 Biogen Idec Ma Inc. Methods For Detecting Half-Antibodies Using Chip Based Gel Electophoresis
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20050283385A1 (en) 2004-06-21 2005-12-22 The Permanente Medical Group, Inc. Individualized healthcare management system
EP2258400A3 (en) 2004-07-08 2011-08-10 Elan Pharmaceuticals, Inc. Multivalent VLA-4 antagonists comprising polymer moieties
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN101111263A (zh) 2004-12-03 2008-01-23 比奥根艾迪克Ma公司 推迟或阻止发生多发性硬化
WO2006112951A2 (en) 2005-03-03 2006-10-26 Seedlings Life Science Ventures, Llc Method of risk management for patients undergoing natalizumab treatment
DK3264094T3 (da) 2005-04-04 2020-11-23 Biogen Ma Inc Fremgangsmåder til evaluering af en immunrespons på et terapeutisk middel
DE602006019296D1 (de) 2005-09-29 2011-02-10 Elan Pharm Inc Pyrimidinylamidverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
CA2643838A1 (en) 2006-02-27 2007-09-07 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
EP2007392A4 (en) 2006-02-28 2010-04-07 Elan Pharm Inc METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4-INHIBITABLE COMPOUNDS
ES2663377T3 (es) 2006-03-03 2018-04-12 Biogen Ma Inc. Métodos para el tratamiento de enfermedades inflamatorias y autoinmunes con natalizumab
EP1873201B1 (en) * 2006-06-30 2010-09-29 Sumitomo Rubber Industries, Ltd. Rubber composition for cap tread and pneumatic tire having cap tread using same
EP2089515A4 (en) 2006-11-16 2011-02-23 Novavax Inc VIRUSUAL PARTICLES OF RESPIRATORY SYNZYTIAL VIRUS
EP1933140B1 (en) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Antibody detection method involving an oligonucleotide enhanced collodial gold signal
BRPI1016273A2 (pt) 2009-02-05 2020-12-01 Biogen Idec Ma Inc. método para a detecção de polimavírus jc
US9354233B2 (en) 2009-02-20 2016-05-31 The Regents Of The University Of California A+ biomarker assays
CN102906278A (zh) * 2010-01-11 2013-01-30 比奥根艾迪克Ma公司 用于jc病毒抗体的测定
EP4187248A1 (en) 2011-05-31 2023-05-31 Biogen MA Inc. Method of assessing risk of pml

Also Published As

Publication number Publication date
JP2016040557A (ja) 2016-03-24
ES2930469T3 (es) 2022-12-14
DK2524060T3 (en) 2018-03-12
RS63744B1 (sr) 2022-12-30
IN2012DN06139A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-18
RS66509B1 (sr) 2025-03-31
KR20120112621A (ko) 2012-10-11
CY1126069T1 (el) 2023-11-15
US9316641B2 (en) 2016-04-19
SMT201800148T1 (it) 2018-05-02
MX341991B (es) 2016-09-09
EP2524060B1 (en) 2017-11-29
LT3339865T (lt) 2022-12-12
ES3012733T3 (en) 2025-04-10
US20130022961A1 (en) 2013-01-24
LT2524060T (lt) 2018-03-26
WO2011085369A1 (en) 2011-07-14
EP3339865B9 (en) 2022-12-14
EP4152004B9 (en) 2025-04-09
SG10201500079YA (en) 2015-03-30
EP3339865B1 (en) 2022-08-24
SG181653A1 (en) 2012-07-30
BR112012017014A2 (pt) 2016-04-05
NO2524060T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-04-28
AU2011203815B2 (en) 2015-11-26
HUE070903T2 (hu) 2025-07-28
CN102906278A (zh) 2013-01-30
EP3339865A1 (en) 2018-06-27
PL4152004T3 (pl) 2025-03-24
PT3339865T (pt) 2022-11-22
KR101877576B1 (ko) 2018-07-12
SI3339865T1 (sl) 2023-01-31
HRP20250210T1 (hr) 2025-04-11
US20160187337A1 (en) 2016-06-30
US10444234B2 (en) 2019-10-15
JP2013516633A (ja) 2013-05-13
EP2524060A4 (en) 2013-10-09
AU2011203815A1 (en) 2012-07-05
HUE060312T2 (hu) 2023-02-28
HRP20180356T1 (hr) 2018-04-06
CY1119972T1 (el) 2018-12-12
PT4152004T (pt) 2025-02-18
JP5946218B2 (ja) 2016-07-05
SMT202500065T1 (it) 2025-03-12
DK3339865T3 (da) 2022-11-28
FI4152004T3 (fi) 2025-02-21
SMT202200445T1 (it) 2023-01-13
MX2012007660A (es) 2012-07-25
NZ600681A (en) 2014-10-31
DK3339865T5 (da) 2023-03-20
BR112012017014B1 (pt) 2021-07-20
ME03026B (me) 2018-10-20
LT4152004T (lt) 2025-02-25
PL2524060T3 (pl) 2018-05-30
FI3339865T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-11-30
DK4152004T3 (da) 2025-02-24
EP2524060A1 (en) 2012-11-21
HRP20221390T1 (hr) 2023-01-06
HUE036183T2 (hu) 2018-06-28
BR112012017014A8 (pt) 2018-06-05
RS56977B1 (sr) 2018-05-31
HK1255318A1 (en) 2019-08-16
CA2784137A1 (en) 2011-07-14
EP4524571A3 (en) 2025-06-11
FI3339865T5 (fi) 2023-04-15
ES2664173T3 (es) 2018-04-18
EP4152004A1 (en) 2023-03-22
SI2524060T1 (en) 2018-05-31
EP4524571A2 (en) 2025-03-19
EP4152004B1 (en) 2024-11-20
SI4152004T1 (sl) 2025-04-30
PL3339865T3 (pl) 2022-12-19

Similar Documents

Publication Publication Date Title
FI3339865T5 (fi) Jc-viruksen vasta-aineiden määritys
ZA201209004B (en) Anti-fgfr2 antibodies
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
PT3342786T (pt) Anticorpo anti-dll3
ZA201208541B (en) Antibody preparations
PL2603528T3 (pl) Przeciwciała Fab-glikozylowane
GB201020738D0 (en) Antibodies
ZA201302459B (en) Antibodies
GB201002238D0 (en) Antibodies
ZA201302160B (en) Serum preparation
GB201005062D0 (en) Antibodies
GB201020751D0 (en) Antibodies